{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:47:58Z","timestamp":1774363678164,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00280-017-3424-4","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T08:59:41Z","timestamp":1503478781000},"page":"829-839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9093-0548","authenticated-orcid":false,"given":"Islem","family":"Ben Hassine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanene","family":"Gharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hind","family":"Ben Hadj Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahlem","family":"Farrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassiba","family":"Amouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouheb","family":"Teber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hela","family":"Ghedira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosra","family":"Ben Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Safra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salem","family":"Abbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Menif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,23]]},"reference":[{"key":"3424_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243:290\u2013293. doi:\n                        10.1038\/243290a0","journal-title":"Nature"},{"key":"3424_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4065\/81.7.973","volume":"81","author":"A Quint\u00e1s-Cardama","year":"2006","unstructured":"Quint\u00e1s-Cardama A, Cortes JE (2006) Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 81:973\u2013988. doi:\n                        10.4065\/81.7.973","journal-title":"Mayo Clin Proc"},{"key":"3424_CR3","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928\u20131937. doi:\n                        10.1182\/blood.V99.6.1928","journal-title":"Blood"},{"key":"3424_CR4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 8:1018\u20131029. doi:\n                        10.1016\/S1470-2045(07)70342-X","journal-title":"Lancet Oncol"},{"key":"3424_CR5","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118:1208\u20131215. doi:\n                        10.1182\/blood-2010-12-326405","journal-title":"Blood"},{"key":"3424_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/10245332.2016.1252020","volume":"22","author":"I Soltani","year":"2017","unstructured":"Soltani I, Douzi K, Gharbi H et al (2017) Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance. Hematology 22:201\u2013207. doi:\n                        10.1080\/10245332.2016.1252020","journal-title":"Hematology"},{"key":"3424_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00280-017-3266-0","volume":"79","author":"I Ben Hassine","year":"2017","unstructured":"Ben Hassine I, Gharbi H, Soltani I et al (2017) hOCT1 gene expression predict for optimal response to imatinib in Tunisian patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 79:737\u2013745. doi:\n                        10.1007\/s00280-017-3266-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"3424_CR8","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104:3739\u20133745. doi:\n                        10.1182\/blood-2003-12-4276","journal-title":"Blood"},{"key":"3424_CR9","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","volume":"112","author":"S Dulucq","year":"2008","unstructured":"Dulucq S, Bouchet S, Turcq B et al (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112:2024\u20132027. doi:\n                        10.1182\/blood-2008-03-147744","journal-title":"Blood"},{"key":"3424_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","volume":"28","author":"L-N Ni","year":"2011","unstructured":"Ni L-N, Li J-Y, Miao K-R et al (2011) Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 28:265\u2013269. doi:\n                        10.1007\/s12032-010-9456-9","journal-title":"Med Oncol"},{"key":"3424_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","volume":"75","author":"C Marzolini","year":"2004","unstructured":"Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13\u201333. doi:\n                        10.1016\/j.clpt.2003.09.012","journal-title":"Clin Pharmacol Ther"},{"key":"3424_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","volume":"21","author":"LM Hodges","year":"2011","unstructured":"Hodges LM, Markova SM, Chinn LW et al (2011) Very important pharmacogene summary. Pharmacogenet Genomics 21:152\u2013161. doi:\n                        10.1097\/FPC.0b013e3283385a1c","journal-title":"Pharmacogenet Genomics"},{"key":"3424_CR13","first-page":"445","volume":"65","author":"AJ-L Brambila-Tapia","year":"2013","unstructured":"Brambila-Tapia AJ-L (2013) MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Invest Cl\u00edn Org Hosp Enfermedades Nutr 65:445\u2013454","journal-title":"Rev Invest Cl\u00edn Org Hosp Enfermedades Nutr"},{"key":"3424_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0279-y","author":"MAM Ali","year":"2014","unstructured":"Ali MAM, Elsalakawy WA (2014) ABCB1 haplotypes but not individual SNPs predict for optimal response\/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate. Med Oncol. doi:\n                        10.1007\/s12032-014-0279-y","journal-title":"Med Oncol"},{"key":"3424_CR15","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3892\/ol.2014.1857","volume":"7","author":"D Vivona","year":"2014","unstructured":"Vivona D, Lima LT, Rodrigues AC et al (2014) ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. Oncol Lett 7:1313\u20131319. doi:\n                        10.3892\/ol.2014.1857","journal-title":"Oncol Lett"},{"key":"3424_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/PGPM.S45522","volume":"6","author":"K Skoglund","year":"2013","unstructured":"Skoglund K, Moreno SB, Baytar M et al (2013) ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro. Pharmacogenomics Pers Med 6:63\u201372. doi:\n                        10.2147\/PGPM.S45522","journal-title":"Pharmacogenomics Pers Med"},{"key":"3424_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1309\/LMP1ECAE30JSVZEP","volume":"44","author":"S Solali","year":"2013","unstructured":"Solali S, Kaviani S, Movassaghpour AA, Aliparasti MR (2013) Real-time polymerase chain reaction testing for quantitative evaluation of hOCT1 and MDR1 expression in patients with chronic myeloid leukemia resistant to imatinib. Lab Med 44:13\u201319. doi:\n                        10.1309\/LMP1ECAE30JSVZEP","journal-title":"Lab Med"},{"key":"3424_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.leukres.2016.10.005","volume":"51","author":"Vasconcelos F Cunha da","year":"2016","unstructured":"da Cunha Vasconcelos F, Mauricio Scheiner MA, Moellman-Coelho A et al (2016) Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice. Leuk Res 51:3\u201310. doi:\n                        10.1016\/j.leukres.2016.10.005","journal-title":"Leuk Res"},{"key":"3424_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0971-5916.164250","volume":"142","author":"H Malhotra","year":"2015","unstructured":"Malhotra H, Sharma P, Malhotra B et al (2015) Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase. Indian J Med Res 142:175. doi:\n                        10.4103\/0971-5916.164250","journal-title":"Indian J Med Res"},{"key":"3424_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12185-011-0924-6","volume":"94","author":"F Razga","year":"2011","unstructured":"Razga F, Racil Z, Machova Polakova K et al (2011) The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia. Int J Hematol 94:303\u2013306. doi:\n                        10.1007\/s12185-011-0924-6","journal-title":"Int J Hematol"},{"key":"3424_CR21","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884. doi:\n                        10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"3424_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1006\/abio.1987.9999","volume":"162","author":"P Chomzynski","year":"1987","unstructured":"Chomzynski P (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate\u2013phenol\u2013chloroform extraction. Anal Biochem 162:156\u2013159. doi:\n                        10.1006\/abio.1987.9999","journal-title":"Anal Biochem"},{"key":"3424_CR23","first-page":"186","volume":"8","author":"NC Cross","year":"1994","unstructured":"Cross NC, Melo JV, Feng L, Goldman JM (1994) An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 8:186\u2013189","journal-title":"Leukemia"},{"key":"3424_CR24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.patbio.2007.12.010","volume":"57","author":"S Menif","year":"2009","unstructured":"Menif S, Zarrouki S, Jeddi R et al (2009) Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia. Pathol Biol 57:388\u2013391. doi:\n                        10.1016\/j.patbio.2007.12.010","journal-title":"Pathol Biol"},{"key":"3424_CR25","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","volume":"3","author":"TD Schmittgen","year":"2008","unstructured":"Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3:1101\u20131108. doi:\n                        10.1038\/nprot.2008.73","journal-title":"Nat Protoc"},{"key":"3424_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method. Methods 25:402\u2013408. doi:\n                        10.1006\/meth.2001.1262","journal-title":"Methods"},{"issue":"532\u2013534","key":"3424_CR27","first-page":"536","volume":"15","author":"P Chomczynski","year":"1993","unstructured":"Chomczynski P (1993) A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15(532\u2013534):536\u2013537","journal-title":"Biotechniques"},{"key":"3424_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2105-13-134","volume":"13","author":"J Ye","year":"2012","unstructured":"Ye J, Coulouris G, Zaretskaya I et al (2012) Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics 13:134. doi:\n                        10.1186\/1471-2105-13-134","journal-title":"BMC Bioinformatics"},{"key":"3424_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/cr.2009.33","volume":"19","author":"Z Li","year":"2009","unstructured":"Li Z, Zhang Z, He Z et al (2009) A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http:\/\/analysis.bio-x.cn). Cell Res 19:519\u2013523. doi:\n                        10.1038\/cr.2009.33","journal-title":"Cell Res"},{"key":"3424_CR30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.cr.7290272","volume":"15","author":"Y Yong","year":"2005","unstructured":"Yong Y, Lin HE (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97\u201398","journal-title":"Cell Res"},{"key":"3424_CR31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","volume":"16","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian HM, Cortes JE (2009) Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control J Moffitt Cancer Cent 16:122\u2013131","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"key":"3424_CR32","first-page":"BR193","volume":"8","author":"W Prejzner","year":"2002","unstructured":"Prejzner W (2002) Relationship of the BCR gene breakpoint and the type of BCR\/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia. Med Sci Monit 8:BR193\u2013BR197","journal-title":"Med Sci Monit"},{"key":"3424_CR33","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","volume":"127","author":"P Jain","year":"2016","unstructured":"Jain P, Kantarjian H, Patel KP et al (2016) Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127:1269\u20131275. doi:\n                        10.1182\/blood-2015-10-674242","journal-title":"Blood"},{"key":"3424_CR34","first-page":"803","volume":"4","author":"JAR Lemos de","year":"2005","unstructured":"de Lemos JAR, de Oliveira CM, Scerni ACC et al (2005) Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Genet Mol Res GMR 4:803\u2013811","journal-title":"Genet Mol Res GMR"},{"key":"3424_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/0971-5851.133707","volume":"35","author":"P Chakrabarti","year":"2014","unstructured":"Chakrabarti P, Chakrabarty S, Aich R et al (2014) Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian J Med Paediatr Oncol 35:26. doi:\n                        10.4103\/0971-5851.133707","journal-title":"Indian J Med Paediatr Oncol"},{"key":"3424_CR36","first-page":"928","volume":"83","author":"C Udomsakdi-Auewarakul","year":"2000","unstructured":"Udomsakdi-Auewarakul C, U-Pratya Y, Boonmoh S, Vatanavicharn S (2000) Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcriptase polymerase chain reaction (RT-PCR). J Med Assoc Thail Chotmaihet Thangphaet 83:928\u2013935","journal-title":"J Med Assoc Thail Chotmaihet Thangphaet"},{"key":"3424_CR37","doi-asserted-by":"publisher","first-page":"22811","DOI":"10.3390\/ijms160922811","volume":"16","author":"M Polillo","year":"2015","unstructured":"Polillo M, Galimberti S, Barat\u00e8 C et al (2015) Pharmacogenetics of BCR\/ABL inhibitors in chronic myeloid leukemia. Int J Mol Sci 16:22811\u201322829. doi:\n                        10.3390\/ijms160922811","journal-title":"Int J Mol Sci"},{"key":"3424_CR38","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00280-017-3271-3","volume":"79","author":"L Galeotti","year":"2017","unstructured":"Galeotti L, Ceccherini F, Domingo D et al (2017) Association of the hOCT1\/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. Cancer Chemother Pharmacol 79:767\u2013773. doi:\n                        10.1007\/s00280-017-3271-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"3424_CR39","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","volume":"35","author":"M Maffioli","year":"2011","unstructured":"Maffioli M, Cam\u00f3s M, Gaya A et al (2011) Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leuk Res 35:1014\u20131019. doi:\n                        10.1016\/j.leukres.2010.12.004","journal-title":"Leuk Res"},{"key":"3424_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.179","author":"LN Eadie","year":"2016","unstructured":"Eadie LN, Dang P, Saunders VA et al (2016) The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia. doi:\n                        10.1038\/leu.2016.179","journal-title":"Leukemia"},{"key":"3424_CR41","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W et al (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15:4750\u20134758. doi:\n                        10.1158\/1078-0432.CCR-09-0145","journal-title":"Clin Cancer Res"},{"key":"3424_CR42","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.1182\/blood-2010-08-298794","volume":"116","author":"S Dulucq","year":"2010","unstructured":"Dulucq S, Preudhomme C, Guilhot F, Mahon F-X (2010) Response: Is there really a relationship between multidrug resistance gene (MDR1) polymorphisms and major molecular response to imatinib in chronic myeloid leukemia? Blood 116:6145\u20136146. doi:\n                        10.1182\/blood-2010-08-298794","journal-title":"Blood"},{"key":"3424_CR43","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/jhg.2010.98","volume":"55","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, Miura M, Scott SA et al (2010) Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 55:731\u2013737. doi:\n                        10.1038\/jhg.2010.98","journal-title":"J Hum Genet"},{"key":"3424_CR44","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.3109\/10428194.2014.893307","volume":"55","author":"J Vine","year":"2014","unstructured":"Vine J, Cohen SB, Ruchlemer R et al (2014) Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia. Leuk Lymphoma 55:2525\u20132531. doi:\n                        10.3109\/10428194.2014.893307","journal-title":"Leuk Lymphoma"},{"key":"3424_CR45","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.biopha.2014.01.009","volume":"68","author":"A Au","year":"2014","unstructured":"Au A, Aziz Baba A, Goh AS et al (2014) Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients. Biomed Pharmacother 68:343\u2013349. doi:\n                        10.1016\/j.biopha.2014.01.009","journal-title":"Biomed Pharmacother"},{"key":"3424_CR46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.2012.066480","volume":"98","author":"S Angelini","year":"2013","unstructured":"Angelini S, Soverini S, Ravegnini G et al (2013) Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 98:193\u2013200. doi:\n                        10.3324\/haematol.2012.066480","journal-title":"Haematologica"},{"key":"3424_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/tpj.2014.54","volume":"15","author":"Q Zheng","year":"2015","unstructured":"Zheng Q, Wu H, Yu Q et al (2015) ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. Pharmacogenomics J 15:127\u2013134. doi:\n                        10.1038\/tpj.2014.54","journal-title":"Pharmacogenomics J"},{"key":"3424_CR48","doi-asserted-by":"publisher","first-page":"154","DOI":"10.5045\/br.2015.50.3.154","volume":"50","author":"M Lardo","year":"2015","unstructured":"Lardo M, Castro M, Moiraghi B et al (2015) MDR1\/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia. Blood Res 50:154. doi:\n                        10.5045\/br.2015.50.3.154","journal-title":"Blood Res"},{"key":"3424_CR49","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3127","author":"C Yin","year":"2016","unstructured":"Yin C, Chen W, Zhong Q et al (2016) Association between the concentration of imatinib in bone marrow mononuclear cells, mutation status of ABCB1 and therapeutic response in patients with chronic myelogenous leukemia. Exp Ther Med. doi:\n                        10.3892\/etm.2016.3127","journal-title":"Exp Ther Med"},{"key":"3424_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0851-5","author":"LT Lima de","year":"2014","unstructured":"de Lima LT, Vivona D, Bueno CT et al (2014) Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Med Oncol. doi:\n                        10.1007\/s12032-014-0851-5","journal-title":"Med Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3424-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3424-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3424-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T13:20:31Z","timestamp":1511184031000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3424-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,23]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["3424"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3424-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,23]]}}}